Tella Inc
TSE:2191

Watchlist Manager
Tella Inc Logo
Tella Inc
TSE:2191
Watchlist
Price: 2 JPY -50% Market Closed
Market Cap: ¥101.3m

Net Margin

-1 005.6%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 005.6%
=
Net Income
¥-898.7m
/
Revenue
¥89.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 005.6%
=
Net Income
¥-898.7m
/
Revenue
¥89.4m

Peer Comparison

Country Company Market Cap Net
Margin
JP
Tella Inc
TSE:2191
101.3m JPY
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
223.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.9B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
81.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.6B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 917 companies
1st percentile
-1 005.6%
Low
-122 700% — 2.9%
Typical Range
2.9% — 8.5%
High
8.5% — 63 031.4%
Distribution Statistics
Japan
Min -122 700%
30th Percentile 2.9%
Median 5.4%
70th Percentile 8.5%
Max 63 031.4%

Tella Inc
Glance View

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. The company is headquartered in Shinjuku, Tokyo-To and currently employs 30 full-time employees. The company went IPO on 2009-03-26. The firm operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.

Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 005.6%
=
Net Income
¥-898.7m
/
Revenue
¥89.4m
How has Net Margin changed over time?

Over the last 3 years, Tella Inc’s Net Margin has decreased from -191.9% to -1 005.6%. During this period, it reached a low of -1 510.4% on Mar 31, 2021 and a high of -177.3% on Jun 30, 2019.

Back to Top